ClinicalTrials.gg

Program

TQC3721

A development code. Also written as “TQC3721 suspension for inhalation”, “TQC3721 inhalation powder” and “TQC3721 Suspension for Inhalation”.

In Sino Biopharmaceutical's pipeline, PDE3/4抑制剂. Its studies are mostly in Pulmonary Disease, Chronic Obstructive, led by Sino Biopharmaceutical.

Furthest: phase 3, since Aug 22, 20258 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical82 open or runningphase 3since Aug 22, 2025Aug 17, 2021Feb 2027phase 3 · NCT07464587
  • Named in Sino Biopharmaceutical’s own pipeline as TQC3721, phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 17, 2021First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT05051930 · 114 enrolled · China
  2. Mar 15, 2022Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT05292196 · 59 enrolled · China
  3. Aug 4, 2023Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT05987371 · 75 enrolled · China
  4. Jul 24, 2024Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06527144 · 240 enrolled · China
  5. Dec 18, 2024Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06748079 · 113 enrolled · China
  6. Aug 22, 2025Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07147946 · 666 planned · China
  7. Nov 19, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07252908 · 195 enrolled · China
  8. Mar 7, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07464587 · 800 planned · China

Ahead

  1. Feb 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07464587
  2. Mar 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07147946

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07464587Pulmonary Disease, Chronic Obstructive · China3RecruitingFeb 2027800
NCT07252908Pulmonary Disease, Chronic Obstructive · China2CompletedApr 28, 2026195
NCT07147946Pulmonary Disease, Chronic Obstructive · China3Not yet recruitingMar 2027666
NCT06748079Pulmonary Disease, Chronic Obstructive · China1CompletedAug 7, 2026113
NCT06527144Pulmonary Disease, Chronic Obstructive · China2CompletedJan 16, 2025240
NCT05987371Pulmonary Disease, Chronic Obstructive · China2CompletedJan 16, 202475
NCT05292196Pulmonary Disease, Chronic Obstructive · China2TerminatedJan 11, 202359
NCT05051930Pulmonary Disease, Chronic Obstructive · China1UNKNOWNOct 31, 2022114

How it is read

Names in the registry

  • “TQC3721 suspension for inhalation”, 3 entries
  • “TQC3721 inhalation powder”, 2 entries
  • “TQC3721 Suspension for Inhalation”, 1 entry
  • “TQC3721 inhalation powder combined with glyberlam inhalation powder or a control group”, 1 entry
  • “TQC3721 Suspension for inhalation”, 1 entry

Codes read as this program: TQC3721.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
TQC3721 (Sino Biopharmaceutical): development program | ClinicalTrials.gg